JANL 最新10-Q变化
将 JANL 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-07 与上一份 10-Q · 2026-05-08
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +9 | −8 | ~37 | 29 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~2 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素、其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-07
On April 8, 2026, the Company acquired an antibody product line from BioPorto A/S. The transaction was accounted for as an asset acquisition. The total purchase price was $10,000, consisting of $9,000 in cash paid at closing and contingent consideration with an acquisition-date fair value of $1,000.…
On May 1, 2026, the Company acquired all the rights, title and interests to a royalty agreement for certain antibody products, which the Company includes in the Life Sciences segment. The transaction was accounted for as an asset acquisition. The total consideration transferred was approximately $1,…
Adjusted operating income for the three months ended June 30, 2026 increased to $5,199 from $2,770 in the prior year period. Adjusted operating income for the nine months ended June 30, 2026 increased to $9,820 from $7,825 in the prior year period. The increase in adjusted operating income for the t…
Selling, general and administrative expenses for the nine months ended June 30, 2026 were $33,494 as compared to $28,327 for the nine months ended June 30, 2025. This increase of $5,167, or 18.2% , was mainly due to prior year acquisitions. Selling, general and administrative expenses as a percentag…
Income from operations increased to $5,505 for the three months ended June 30, 2026 as compared to income from operations of $2,538 for the three months ended June 30, 2025, an increase of $2,967, or 116.9%. Operating margin as a percentage of gross profit for the three months ended June 30, 2026 wa…
相对上期删除的文字 · 来源:10-Q · 2026-05-08
Adjusted operating income for the three months ended March 31, 2026 decreased to $2,593 from $3,014 in the prior year period. Adjusted operating income for the six months ended March 31, 2026 decreased to $4,621 from $5,055 in the prior year period. The decrease in adjusted operating income for both…
Selling, general and administrative expenses for the six months ended March 31, 2026 were $21,891, as compared to $18,892 for the six months ended March 31, 2025. This increase of $2,999, or
15.9%, was mainly due to the Interlog and RW Smith acquisitions, partially offset by a reduction in various expenses, including personnel costs. Selling, general and administrative expenses as a percentage of revenues were 21.4% and 21.0% of revenues for the six months ended March 31, 2026 and 2025,…
Income from operations increased to $3,466 for the three months ended March 31, 2026, as compared to income from operations of $2,332 for the three months ended March 31, 2025, an increase of $1,134, or 48.6%. Operating margin as a percentage of gross profit for the three months ended March 31, 2026…
Income from operations increased to $6,888 for the six months ended March 31, 2026, as compared to $4,342 for the six months ended March 31, 2025, an increase of $2,546, or 58.6%. Operating margin as a percentage of gross profit for the six months ended March 31, 2026 was 23.9% compared to 18.7% in …
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议